This site is intended for health professionals only

Flu-treatment breakthrough trial


A “one-shot” flu-treatment breakthrough is the hoped-for outcome of phase III trials due to begin in Japan, Taiwan, Hong Kong and Korea.

Daiichi Sankyo’s CS-8958 drug is a long-acting neuraminidase inhibitor (LANI) that has shown promise against the H5N1 avian influenza virus as well as influenza A and B.

It is expected that a single inhalation will be as effective as 75mg of oseltamivir administered orally twice daily for five days.

The double-blind non-inferiority study will use symptom resolution and fever as its endpoints after a single inhaled dose. The safety of CS-8958 will also be assessed.

The study is named MARVEL (Multinational Asian clinical Research for influenza Virus Extermination on LANI). In the phase II/III trial for paediatrics, it is hoped that symptom resolution and fever with the same dose regimens will be confirmed.

Copyright Press Association 2008


Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine